Obesity is becoming a global epidemic and a major contributor to the increased incidence of serious chronic diseases, such as type 2 diabetes, CVD, hepatic and skeletal muscle insulin resistance, and certain types of cancer^(^[@ref1]^)^. The main cause of obesity is an imbalance between energy intake and expenditure. However, there is a growing body of evidence that not only energy intake and expenditure habits explain the increasing prevalence of obesity; environmental factors contribute as well^(^[@ref2]^)^.

Even within monozygotic twins, some individuals are more prone to weight gain, suggesting that factors other than the human genome are involved in the development of obesity^(^[@ref3]^)^. The gut microbiota is an example of an environmental factor that may affect the development of obesity. Recent evidence suggests that the gut microbiota has a supporting function in regulating energy balance, fat storage, neurohormonal functions and immune systems^(^[@ref4]^--^[@ref7]^)^. Accordingly, recent studies have suggested that manipulating the composition of the microbial ecosystem in the gut may be a novel approach in the treatment of obesity. Such treatment might consist of altering the composition of the microbial communities of an obese individual by administering beneficial micro-organisms, commonly known as probiotics^(^[@ref2]^)^.

In the context of obesity, several studies have reported that a low number of *Bifidobacterium* spp. is correlated with the development of obesity and/or diabetes^(^[@ref8]^--^[@ref10]^)^. Furthermore, Cani *et al.*^(^[@ref11]^,^[@ref12]^)^ demonstrated that diet-induced obesity (DIO) (high-fat--low-carbohydrate diet) in mice markedly affects the gut microbial community, in which the levels of *Bifidobacterium* spp. were significantly reduced, in agreement with observations in human subjects. Ilmonen *et al.*^(^[@ref13]^)^ applied *Lactobacillus rhamnosus* together with *Bifidobacterium lactis* Bb12 to prevent obesity during and after pregnancy, which resulted in reduced body weight. Mikirova *et al.*^(^[@ref14]^)^ found that a probiotic combination of both *L. acidophilus* and *B. bifidum* reduced body weight among fifty-three obese individuals. A double-blind randomised controlled trial by Kadooka *et al.*^(^[@ref15]^)^ demonstrated that the administration of the microbial strain *Lactobacillus gasseri* SBT2055 reduced adiposity and body weight. The authors also demonstrated the reproducible effect of SBT2055 to lower the visceral fat mass, BMI, and waist and hip circumferences by a randomised controlled trial using fermented milk with a lower concentration of *L. gasseri* SBT2055.

Along with the evidence of the therapeutic effects of probiotic bacteria against obesity, some mechanisms of action have been proposed, such as an effect on appetite regulation, host metabolism, the inhibition of lipid absorption, the maintenance of intestinal homeostasis and integrity, and low-grade inflammation^(^[@ref16]^--^[@ref18]^)^. However, the effects of these probiotic bacteria are believed to be strain dependent, and the underlying mechanism remains unclear^(^[@ref19]^)^. To establish a therapeutic approach by which the administration of probiotic bacteria can prevent obesity, further research for each bacterial strain is necessary.

We previously reported that the administration of a probiotic strain *B. breve* B-3 in a mouse model of DIO reduced body-weight gain and visceral fat deposits in a dose-dependent manner and improved the serum levels of total cholesterol, glucose and insulin^(^[@ref20]^)^. However, the effect of this strain on human subjects has not yet been investigated.

Here, we conducted a randomised, double-blind, parallel-group comparative study to examine whether the consumption of a capsule containing live *B. breve* B-3 effects body composition and blood parameters in adults with a tendency for obesity.

Subjects and methods {#sec1}
====================

Trial design {#sec1-1}
------------

The present study was designed as a randomised, double-blind, parallel-group comparative study. The protocol was in accordance with the Declaration of Helsinki. All of the participants provided written informed consent. All of the study protocols were approved and controlled by the Ethics Committee of Tokyo Healthcare University (Tokyo Japan). The study was performed from January to June 2012 at the Nakajima medical clinic in Kanagawa Prefecture, Japan.

Participants {#sec1-2}
------------

A total of fifty-two adult volunteers were recruited based on their BMI (ranging from 24 to 30 kg/m^2^) and age (ranging from 40 to 69 years) at the Nakajima medical clinic. Most of the participants were under clinical practice for diabetes including nutrition education and medication. The exclusion criteria included regular ingestion of diet foods or supplements for lowering body fat or cholesterol (more than twice per week), ingestion of products with probiotic bacteria that could affect the microbiota as an intestinal regulator, a history of severe diseases of the liver, kidney, heart, lung, digestive organs, blood, endocrine system or metabolic pathway, and the presence of a food allergy or drug allergy. A flowchart of participants is shown in [Fig. 1](#fig01){ref-type="fig"}. Fig. 1.Participant flowchart. B-3, *Bifidobacterium breve* B-3.

Procedure {#sec1-3}
---------

The study period consisted of a 4-week run-in period, followed by a 12-week ingestion period. Initially, during the run-in period, the participants were instructed to complete a questionnaire of body measurements, lifestyle habits (intake of yogurt, smoking and alcohol drinking), disorders, allergies and regular medications. Each subject made a daily record of their alcohol drinking, exercise and activities, usage of drugs, defecation and physical condition. For the body composition and blood test, the baseline measurement took place at the end of the 4-week run-in period, which was regarded as week 0. After the run-in period, the participants were stratified by sex and BMI (above 27 or less than 27 kg/m^2^) and randomly divided into two groups according to computer-generated permuted-block randomisation at Tokyo Healthcare University. Each group was then randomised to receive three capsules of placebo capsule or B-3 capsule daily for 12 weeks. During the study, the participants were advised not to change their regular lifestyles, including their diet, exercise and regular medications. Then, the subjects initiated the intake of B-3 or the placebo capsule and visited the clinic to receive physical measurements, blood sampling and a medical interview every 4 weeks, i.e. at 4, 8 and 12 weeks after the initiation of capsule intake.

Test samples {#sec1-4}
------------

The capsules of B-3 contained lyophilised powder of *B. breve* B-3, a strain originating from a healthy infant, and had mainly maize starch as the carrier in an acid-protective gelatin capsule. The placebo capsule only included an internal matrix (mainly maize starch). We confirmed that the B-3 capsules contained approximately 5 × 10^10^ colony-forming units per three capsules by microbial colony count using reinforced clostridial agar (Oxoid) before the clinical trial. The B-3 and placebo capsules appeared and tasted identical.

Outcomes {#sec1-5}
--------

Changes in body composition (body weight, BMI, muscle mass, fat mass, fat percentage, waist:hip ratio) and blood parameters (blood lipids, blood glucose, liver function, inflammatory parameters) at 12 weeks were the primary and secondary outcomes, respectively. Body weight, muscle mass and body fat (amount and percentage) were measured by the bioelectrical impedance method using the medical-grade measurement device InBody3.0 (Takumi). BMI was calculated as body weight (kg)/height (m[@ref2]). The waist:hip ratio was calculated based on the waist circumference and hip circumference. Blood analysis was performed at Health Science Research Institute Co., Ltd (Tokyo, Japan).

Statistical analysis {#sec1-6}
--------------------

SAS software version 9.3 (SAS Institute, Inc.) was used for statistical analyses. Variables that did not follow a normal distribution were analysed after natural log transformation. For clarity, the values are presented according to the original scale in the tables. The baseline characteristics were compared with a Fisher\'s exact test for categorical variables and a two-sample *t* test for continuous variables. For the primary and secondary outcomes, a comparison at 12 weeks was performed between the experimental groups using ANCOVA adjusted for the baseline (week 0). The within-group change at each time point (weeks 4, 8 and 12) from the baseline (week 0) was analysed using a one-sample *t* test. The correlation between the changing values in the fat mass and those of the other parameters between 0 and 12 weeks were analysed using Pearson\'s correlation, followed by standardising each variable (*z* score). A *P* value \<0·05 was considered statistically significant.

Results {#sec2}
=======

Baseline characteristics of participants {#sec2-1}
----------------------------------------

Of the participants, four in the B-3 group and two in the placebo group withdrew from the intervention due to personal reasons. One individual in each group reported a serious change of lifestyle (being on a diet by dietary restriction) during the test period; therefore, these participants were removed from the analysis. Thus, the final datasets for the present study were nineteen for the B-3 group and twenty-five for the placebo group ([Fig. 1](#fig01){ref-type="fig"}). The baseline values of the subject demographics, physical characteristics, prescribed drug usage (for diabetes mellitus, hyperlipidaemia and hypertension) and metabolic markers (TAG, fasting blood sugar and HDL-cholesterol) did not differ significantly between the B-3 and placebo groups ([Table 1](#tab01){ref-type="table"}). Compliance was high for sample ingestion: 98·4 ([sem]{.smallcaps} 2·6) and 102·5 ([sem]{.smallcaps} 2·2) % in the B-3 and placebo groups, respectively. Table 1.Baseline characteristics of the subjects(Mean values with their standard errors or number or percentage of participants)Group...Placebo*Bifidobacterium breve* B-3Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}*P*\*Sex (*n*)25190·535Male116Female1413Age (years)61·91·958·92·00·302Body weight (kg)71·22·368·92·70·506BMI (kg/m^2^)27·70·527·10·60·461Muscle mass (kg)45·12·044·82·10·908Fat mass (kg)23·51·021·51·00·187Fat percentage (%)33·31·331·31·00·276Prescribed drug use (%)For diabetes mellitus72790·734For hyperlipidaemia52680·358For hypertension36420·760Metabolic markers (%)TAG ≥ 1·7 mmol/l†60420·361Fasting blood sugar ≥ 6·1 mmol/l†84790·709HDL-cholesterol \< 1·0 mmol/l†451·000[^1][^2]

Effect on body composition {#sec2-2}
--------------------------

[Table 2](#tab02){ref-type="table"} shows the transition of each body composition during the intervention. As a primary outcome, the changes in body composition at 12 weeks were analysed by ANCOVA. A significantly lowered fat mass was observed in the B-3 group compared with the placebo group. A tendency for an inter-group difference was observed for the fat percentage, but there was no significant difference for the other parameters between the two groups. During the intervention, a significant decrease from the baseline (week 0) was observed for body weight (weeks 4 and 12 for the B-3 group; week 4 for the placebo group), BMI (week 4 for both groups), fat mass (weeks 4 and 12 for the B-3 group), fat percentage (week 12 for the B-3 group) and waist:hip ratio (weeks 8 and 12 for both groups). Table 2.Changes in physical examination values(Mean values with their standard errors)Group...Placebo*Bifidobacterium breve* B-3Week 0Week 4Week 8Week 12Week 0Week 4Week 8Week 12Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}*P*†Body weight (kg)71·22·370·4\*2·371·02·370·82·368·92·768·4\*2·668·62·669·1\*2·60·493BMI (kg/m^2^)27·70·527·5\*0·627·60·527·80·527·10·626·9\*0·627·00·627·20·60·403Muscle mass (kg)45·12·044·51·944·91·944·81·944·82·144·82·144·92·145·72·10·376Fat mass (kg)23·51·023·31·123·31·123·41·021·51·021·0\*1·021·00·920·8\*\*0·90·046Fat percentage (%)33·31·333·31·333·21·333·31·231·31·030·81·130·81·030·3\*1·00·066Waist:hip ratio0·9640·00840·9600·00860·958\*0·00850·963\*0·00760·9350·00910·9320·00840·928\*\*0·00810·931\*\*0·00710·174[^3][^4]

Effect of *Bifidobacterium breve* B-3 on blood parameters {#sec2-3}
---------------------------------------------------------

[Table 3](#tab03){ref-type="table"} shows the transition of blood parameters during the intervention. Significant inter-group differences were observed for the values of γ-glutamyltranspeptidase (γ-GTP) (*P* = 0·011) and high-sensitivity C-reactive protein (hCRP) (*P* = 0·039) at week 12. No significant difference was observed for blood lipids (total, LDL- and HDL-cholesterol, TAG) (data not shown). During the intervention, significant increases from the baseline (week 0) were observed for glycated Hb (HbA1c) (weeks 4 and 8 for both groups, week 12 for the placebo group), γ-GTP (week 12 for the placebo group) and total bilirubin (weeks 4 and 8 for the placebo group). Significant decreases from the baseline were observed for insulin (weeks 4 and 8 for the placebo group), alkaline phosphatase (ALP) (week 8 for the B-3 group) and hCRP (week 12 for the B-3 group). Table 3.Changes in blood parameters(Mean values with their standard errors)Group...Placebo*Bifidobacterium breve* B-3Week 0Week 4Week 8Week 12Week 0Week 4Week 8Week 12Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}Mean[sem]{.smallcaps}*P*†Fasting blood glucose (mmol/l)‡8·630·729·031·008·510·888·600·749·880·9010·160·839·390·669·830·710·541HbA1c (%)7·00·37·2\*0·37·2\*0·37·3\*0·37·50·37·8\*0·37·8\*0·37·70·20·249Glycoalbumin (%)18·90·718·80·818·80·719·00·821·01·020·60·820·20·720·33·10·2131,5-Anyhdroglucitol (µg/ml)9·81·310·31·410·51·410·61·46·00·85·70·85·70·86·60·80·725Insulin (µU/ml)‡§39·910·331·8\*8·929·1\*8·639·412·732·06·125·54·325·95·437·78·00·096AST (IU/l)‡26·43·026·62·526·82·627·23·329·75·428·94·527·94·729·55·90·624ALT (IU/l)‡28·62·629·73·130·23·230·63·134·05·335·15·734·25·732·24·90·156ALP (IU/l)‡209·512·3211·913·9203·512·5207·212·0242·720·0241·720·1230·2\*18·0234·318·40·704Lactate dehydrogenase (IU/l)199·07·9197·17·2197·87·8199·48·5197·46·6197·68·3196·28·6197·28·20·936γ-GTP (IU/l)‡39·06·139·67·042·48·144·0\*8·437·07·141·78·139·68·237·87·20·011Total bilirubin (µmol/l)‡8·900·5111·12\*0·6810·60\*0·6810·090·6810·430·8610·770·8610·090·8610·430·860·233hCRP (mg/l)‡0·880·140·900·190·930·181·100·180·980·251·270·321·050·230·90\*0·270·039[^5][^6][^7][^8][^9]

Correlation of changes in body fat mass with blood parameters {#sec2-4}
-------------------------------------------------------------

Significant positive correlations were found between the changed values of the body fat mass and those of alanine aminotransferase (ALT) and γ-GTP; negative correlations were found with 1,5-anhydroglucitol in the B-3 group but not in the placebo group ([Fig. 2](#fig02){ref-type="fig"}). No significant correlation was found between the changed values of the body fat mass and those of other blood parameters. Fig. 2.Correlation analysis between changed values at week 12 from week 0 of body fat mass and blood parameters: (a) γ-glutamyltranspeptidase (γ-GTP); (b) alanine aminotransferase (ALT); (c) 1,5-anhydroglucitol (1,5-AG) by Pearson\'s correlation test. Data shown are correlation coefficients (ρ) with *P* values. \* *P* \< 0·05. For ALT and γ-GTP, correlation analysis was performed using the data after logarithmic transformation and standardisation. (--------, ●), *Bifidobacterium breve* B-3 (B-3) group; (\-\-\--, ○), placebo group.

Discussion {#sec3}
==========

We conducted this clinical trial to examine whether the intake of capsules containing a single strain of live *B. breve* B-3 could influence the obese tendencies of adults. In the present study, the B-3 group did not show a significant reduction in body weight compared with the placebo group; however, the fat mass was significantly reduced by the intake of capsules containing probiotic *B. breve* B-3 for 12 weeks. The decreased fat mass was 0·7 kg on average after 12 weeks in the B-3 group. Similar results were observed by Kadooka *et al*.^(^[@ref15]^)^, who showed an average of 0·6 kg reduction in body fat mass after a 12-week ingestion of a *Lactobacillus* strain, *L. gasseri* SBT2055. Although strict diet restriction may induce a dramatic change in fat mass (for example, −12·4 kg after intake of 2090 kJ (500 kcal)/d for 5 weeks), such a serious diet programme may be accompanied by the risk of a rebound effect due to the declined muscle mass and lowered basal metabolism. Also there would be concerns about the difficulty in continuation. There is considerable evidence that visceral fat obesity is a key aetiological factor for the development of metabolic syndromes, and the excess accumulation of visceral fat is primarily involved in metabolic disorders^(^[@ref21]^,^[@ref22]^)^. The present results suggest the potential of *B. breve* B-3 in the prevention of chronic diseases triggered by adiposity in a sustainable way. Since the intervention was only 12 weeks, future study is needed to evaluate the long-term effects of *B. breve* B-3 ingestion.

In the present study, the participants were recruited at a medical clinic, and most of them were under clinical practice for diabetes. [Table 1](#tab01){ref-type="table"} shows that there was no difference in drug usage between the two groups. In addition, these regular medications were not changed during the intervention. Some participants were prescribed sulfonylureas (56 % in the placebo group and 53 % in the B-3 group) and thiazolidinediones (24 % in the placebo group and 16 % in the B-3 group), diabetes mellitus drugs which have been suggested to affect body weight^(^[@ref23]^)^; however, there was no significant difference between the two groups. Since most of the participants were under clinical practice for diabetes including nutrition education and medication, the values with relation to diabetes such as fasting blood glucose, HbA1c, glycoalbumin and insulin tended to be higher than the normal levels at baseline ([Tables 1](#tab01){ref-type="table"} and [3](#tab03){ref-type="table"}). No significant improvement was found in these parameters by B-3 intake as compared with the placebo group during the intervention; however, there was a tendency of improvement for the values of glycoalbumin, a parameter known to reflect the most recent blood glucose status, in the B-3 group (*P* = 0·081 at week 12) ([Table 3](#tab03){ref-type="table"}). In addition, there were significant increases in the levels of HbA1c, a parameter known to reflect blood glucose levels for the previous 2--3 months, during the intervention in the placebo group, but this was disappeared in the B-3 group at week 12 ([Table 3](#tab03){ref-type="table"}). Interestingly, there was a significant negative correlation between the changed values of fat mass and 1,5-anhydroglucitol, a parameter known to closely reflect diabetic control within several days, in the B-3 group but not the placebo group at week 12 ([Fig. 2](#fig02){ref-type="fig"}). These results suggest the potential of B-3 in the improvement of diabetes, although further investigation with long-term treatment is needed.

In the present study, we also observed a significant improvement in γ-GTP, which correlated with the reduction of fat mass during the consumption period. The correlation between serum γ-GTP levels and risk of the metabolic syndrome has been indicated in large-scale investigations performed in Korea and Japan^(^[@ref24]^,^[@ref25]^)^. Clinically, evaluations of serum γ-GTP levels are widely used as markers to evaluate the degree of liver injury^(^[@ref26]^,^[@ref27]^)^. In addition, γ-GTP has been used as a marker of hepatobiliary tract function and excessive alcohol consumption^(^[@ref28]^--^[@ref30]^)^. A stronger correlation between serum γ-GTP level and metabolic syndrome risk factors was observed in a non-drinker subgroup compared with all other study subjects^(^[@ref31]^)^. Aller *et al.*^(^[@ref32]^)^ reported that the administration of a tablet of 500 million *Lactobacillus bulgaricus* and *Streptococcus thermophilus* improved liver aminotransferases levels in patients with non-alcoholic fatty liver disease. In a pilot study, short-term oral supplementation with *Bifidobacterium bifidum* and *Lactobacillus plantarum* 8PA3 was associated with an improvement in alcohol-induced liver injury compared with standard therapy alone^(^[@ref33]^)^; however, the effect of probiotics in the improvement of γ-GTP has not be previously evaluated. Although the mechanism of probiotics in the improvement of liver function has not yet been adequately evaluated, the results observed in the present study are in agreement with our previous experimental result showing that feeding DIO mice *B. breve* B-3 led to the regulated gene expression of pathways involved in lipid metabolism, as well as responses to stress in the liver^(^[@ref34]^)^.

Accumulating evidence indicates that obesity is associated with a state of chronic, low-grade inflammation, suggesting that inflammation may be a potential mechanism by which obesity leads to insulin resistance^(^[@ref35]^--^[@ref38]^)^. In the early stages of obesity, adipocytes become hypertrophied in response to overnutrition. With increasing adiposity, adipose tissue releases signals such as monocyte chemoattractant protein-1, causing increased monocyte influx^(^[@ref39]^)^. In the advanced stages of obesity, various types of immune cells, such as macrophages, infiltrate into obese adipose tissue and thus enhance the inflammatory changes through cross-talk with adipose tissue-released NEFA^(^[@ref40]^,^[@ref41]^)^. Lipopolysaccharides (LPS) have been suggested to be involved in the development of metabolic syndromes associated with high fat intake^(^[@ref11]^,^[@ref42]^,^[@ref43]^)^. These reports described that mice fed on a high-fat diet for 2 to 4 weeks exhibited a significant increase in plasma LPS. This increase in plasma LPS induced by a high-fat diet suggests metabolic endotoxaemia, which is considered to trigger the development of obesity, inflammation, insulin resistance, type 2 diabetes and atherosclerosis via activation of the CD14/Toll-like receptor 4 complex by LPS and/or fatty acids. However, supplementation with oligofructose stimulates bifidobacterial growth and lowers the uptake of LPS from the gut lumen^(^[@ref11]^)^. This effect is also correlated with an improved glucose tolerance and insulin sensitivity. Hoarau *et al.*^(^[@ref44]^)^ reported that the supernatant fraction of *B. breve* C50 can induce prolonged dendritic cell survival, with oppositional action on the maturation--apoptosis programme induced by LPS. The *B. breve* supernatant fraction alone was reported to be a poor cytokine inducer but may have immunomodulatory properties^(^[@ref45]^)^. Jeon *et al.*^(^[@ref46]^)^ found that *B. breve* but not *L. casei* induced the development of IL-10-producing Tr1 cells in the large intestine, which demonstrates that *B. breve* prevents intestinal inflammation. In the present study, the 12-week intake of *B. breve* B-3 resulted in significantly decreased hCRP levels compared with the placebo group ([Table 3](#tab03){ref-type="table"}). In our previous study, we observed the down-regulation of the expression of acute-phase proteins, such as *Saa* and *Orm*, by administering *B. breve* B-3 to DIO mice, together with the suppression of body-weight gain and fat accumulation^(^[@ref34]^)^. These results suggest that *B. breve* B-3 may function in suppressing the pro-inflammatory reaction related to obesity.

In summary, the 12-week intake of the probiotic *B. breve* B-3 reduced the fat mass of adult subjects with obese tendencies. Possible improvement was also observed for liver function and the systemic inflammatory reaction by *B. breve* B-3 administration. No serious adverse events were observed by medical interview or measurements of blood parameters. *B. breve* B-3 is capable of producing SCFA, such as acetic acid and lactic acid, and other bioactive components, such as conjugated linoleic acid and other fatty acid metabolites, which are possibly involved in the anti-metabolic syndrome effect. A further large-scale randomised controlled trial is needed to confirm the clinical effect of *B. breve* B-3 on improving metabolic function. A study is underway to identify the active components of *B. breve* B-3 involved in the anti-metabolic syndrome effect.
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[^1]: \* *P* values of Fisher\'s exact test for categorical data and *P* values of two-sample *t* tests for continuous data are shown.

[^2]: † Proportion of participants with a baseline level higher than the borderline for domestic criteria of the metabolic syndrome in Japan.

[^3]: Mean value within a group was significantly different from that at baseline (week 0): \* *P* \< 0·05, \*\* *P* \< 0·01 (one-sample *t* test).

[^4]: † Differences between the placebo and B-3 groups at week 12 were analysed by ANCOVA, adjusted for baseline (week 0).

[^5]: HbA1c, glycated Hb; AST, aspartate transaminase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; γ-GTP, γ-glutamyltranspeptidase; hCRP, high-sensitivity C-reactive protein.

[^6]: \* Mean value within a group was significantly different from that at baseline (week 0) (*P* \< 0·05; one-sample *t* test).

[^7]: † Differences between the placebo and B-3 groups at week 12 were analysed by ANCOVA, adjusted for baseline (week 0).

[^8]: ‡ Analysis for within-group and intergroup differences was performed after logarithmic transformation of the values.

[^9]: § To convert insulin in µU/ml to pmol/l, multiply by 6·945.
